A 2026 review proposes that SFRP4 may inhibit tumor angiogenesis through integrin-linked disruption of Wnt–β-catenin ...
OncoC4 Inc., a late clinical-stage biopharmaceutical company developing novel medicines for cancer and neurodegenerative ...
A pooled analysis of 19 studies finds that neoadjuvant apatinib-based regimens achieve a 21 percent pathologic complete ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results